63 results
8-K
EX-99.1
ARCT
Arcturus Therapeutics Holdings Inc
7 Mar 24
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
4:05pm
significant progress with the BARDA grant agreement that led to an increase in revenue of $8.8 million. The majority of the annual decrease … for the execution of the CSL collaboration drove the majority of the revenue recognition during the three months ended December 31, 2022.
Operating expenses
S-8
EX-4.3
7mfuwpoguh
30 Jun 22
Registration of securities for employees
4:05pm
8-K
y21g6j2
24 Jun 22
Entry into a Material Definitive Agreement
5:23pm
8-K
EX-10.1
8weo5zjeule1e07gt
24 Jun 22
Entry into a Material Definitive Agreement
5:23pm
DEFR14A
e4cj 5el0kcb9f9rc6w
12 May 22
Revised proxy
5:00pm
8-K
EX-99.1
z8hqj2v3g1
20 Apr 22
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
5:24pm
S-8
EX-4.1
3ebfe
20 Oct 21
Registration of securities for employees
5:23pm